Figure 3.

Transduction of Primary Human Hepatocytes and T Cells with rAAV/BoV Vectors

(A) YFP expression 5 days after transduction of primary human hepatocytes (pHeps) with scAAV-YFP/BoV vectors at the indicated MOIs (n = 3 donors). Expression first became detectable at day 2 (not shown) and then increased over time. Cells were fixed and stained with an FITC-coupled anti-GFP antibody, and nuclei were stained with Hoechst. Scale bar, 50 μm. (B) Gluc activity at 3 and 6 days post-transduction of pHeps with scAAV-Gluc/BoV at an MOI of 1 × 10⁴. Data represent the mean and range of two independent measurements (n = 2 donors). (C) Transduction of primary human T cells with scAAV-Gluc/BoV (MOI = 1 × 10⁴). Gluc activity in the medium was measured 3–12 days post-transduction. Plotted are means ±SEM of three independent experiments (n = 3 donors). For all transductions, Doxorubicin was added to a final concentration of 1 μM/well. Dashed lines indicate the assay background.